Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits

Hemoglobin

Volumn 33, Issue 5, 2009, Pages 361-369

  Leung, Ting Fan ^a   Chu, Yvonne ^a   Lee, Vincent ^a   Cheng, Frankie W T ^a   Leung, Wing Kwan ^a   Shing, Matthew M K ^a   Li, Chi Kong ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bisphosphonate; Bone mineral density (BMD); Osteoporosis; Thalassemia major (TM); Treatment

Indexed keywords

ALFACALCIDOL; CALCIUM CARBONATE; FERRITIN; PAMIDRONIC ACID;

ADOLESCENT; ADULT; BONE DENSITY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FERRITIN BLOOD LEVEL; HIP; HUMAN; LUMBAR SPINE; MALE; OSTEOPOROSIS; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RETROSPECTIVE STUDIES; THALASSEMIA; VITAMIN D; YOUNG ADULT;

EID: 70350688129     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903210377     Document Type: Conference Paper

References (20)

1. Jensen CE, Tuck SM, Agnew JE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol. 1998;103(4):911-915.
2. Filosa A, Di Maio S, Vocca S, et al. Longitudinal monitoring of bone mineral density in thalassaemic patients: genetic structure and osteoporosis. Acta Paediatr. 1997;86(4):342-346.
3. Angastiniotis M, Pavlides N, Aristidou K, et al. Bone pain in thalassemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab. 1998;11 (SUPPL.l. 3):779-784.
4. Glastre C, Braillon P, David L. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab. 1990;70(5):1330-1333.
5. Cheng JC, Leung SS, Lee WT, et al. Determinants of axial and peripheral bone mass in Chinese adolescents. Arch Dis Child. 1998;78(6):524-530.
6. Leung TF, Hung EC, Lam CW, et al. Bone mineral density in children with thalassemia major: determining factors and effects of bone marrow transplantation. Bone Marrow Transplant. 2005;36(4):331-336.
7. Gaudio A, Morabito N, Xourafa A, et al. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Invest. 2008;31(2):181-184.
8. Perifanis V, Vyzantiadis T, Tziomalos K, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with b-thalassemia. Ann Hematol. 2007;86(1): 23-30.
9. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with b-thalassemia: results from a single-center, randomized, placebocontrolled trial. Haematologica. 2006;91(9):1193-1202.
10. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with b-thalassaemia. Br J Haematol. 2003;123(4):730-737.
11. Johnston CC, Melton LJ III, Lindsay R, Eddy D. Clinical indications for bone mass measurement. J Bone Miner Res. 1989;4(1):1-28.
12. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dualenergy X-ray absorptiometry (DEXA). J Pediatr. 2004;144(2):253-257.
13. Wonke B, Jensen C, Hanslip JJ, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab. 1998;11 (SUPPL.l. 3):795-801.
14. Rioja L, Hany Y, Garabedian M, Cournot-Witmer G. Bone disease in children with homozygous b-thalassemia. Bone Miner. 1990;8(1):69-86.
15. Chan YL, Pang LM, Chik KW, et al. Patterns of bone diseases in transfusion-dependent homozygous thalassemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002;32(7):492-497.
16. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int. 2002;13(8):644-649.
17. Gilfillan CP, Strauss BJ, Rodda CP, et al. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int. 2006;79(3):138-144.
18. Voskaridou E, Christoulas D, Konstantinidou M, et al. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica. 2008;93(10):1588-1590.
19. Vogiatzi MG, Macklin EA, Fung EB, et al. Prevalence of fractures among the thalassemia syndromes in North America. Bone. 2006;38(4):571-575.
20. Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24(3):543-557.